학술논문
Longitudinal growth in children with asthma treated with inhaled glucocorticoids / Laengdevaekst hos börn, der har astma og er i behandling med inhalerede glukokortikoider
Document Type
Review
Översikt
Översikt
Author
Source
Ugeskrift for Laeger. 168(9):885
Subject
Language
Danish
ISSN
0041-5782
Abstract
Randomised, double-blind studies with a knemometer have shown that the risk of inhaled glucocorticoid-induced growth suppression depends on dose, administration regimen, delivery device and specific glucocorticoid. Dry-powder beclomethasone dipropionate, 300-400 µ g daily, and budesonide, 400 µ g daily, suppress height growth rate by 20-25% during the first year of treatment, whereas lower doses of budesonide and fluticasone propionate do not affect growth rate. Available assessments of final height are flawed by poor compliance rates. Children with asthma on continuous treatment with inhaled glucocorticoids should have their height measured at six-month intervals. In the case of growth deviation, they should be referred for evaluation.